SEC Form D raise Raised $70M (Form D filed Jul 31, 2026); 7 roles open. SEC Form D 0002004792-26-000001 (Jul 31, 2026)Evidence (1 event)
Jul 31, 2026 · SEC Form D 0002004792-26-000001 Name of Issuer: Ratio Therapeutics, Inc.; CIK: 2004792; Address: Boston, MA; Submission type: D; Filing date: 2026-07-31; Industry Group: Pharmaceuticals; Date of First Sale: 2026-07-16; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 69999974; Total Amount Sold: 69999974; Federal exemptions: 06b
Trial start Early phase 1: A Study of the Pharmacokinetics, Biodistribution and Dosimetry of Granzyme-B Targeted [Cu-64]-Labeled PET Radiotracers in Adult Healthy Volunteers source ↗
Trial start Early phase 1: Exploratory PK and Imaging Study of PSMA-Targeted Trillium Compounds and PTI-122 in Metastatic Prostate Cancer source ↗
Upcoming milestones
2026-12 (ESTIMATED) · Early phase 1 · A Study of the Pharmacokinetics, Biodistribution and Dosimetry of Granzyme-B Targeted [Cu-64]-Labeled PET Radiotracers in Adult Healthy Volunteers · NCT07774650
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
